company background image
AVCO

Avalon GloboCareNasdaqCM:AVCO Stock Report

Last Price

US$0.74

Market Cap

US$65.6m

7D

-0.9%

1Y

-40.2%

Updated

22 Jan, 2022

Data

Company Financials
AVCO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

AVCO Stock Overview

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China.

Price History & Performance

Summary of all time highs, changes and price drops for Avalon GloboCare
Historical stock prices
Current Share PriceUS$0.74
52 Week HighUS$1.65
52 Week LowUS$0.67
Beta0.49
1 Month Change-18.97%
3 Month Change-26.53%
1 Year Change-40.16%
3 Year Change-82.46%
5 Year Change-85.16%
Change since IPO6.00%

Recent News & Updates

Oct 14
Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

AVCOUS HealthcareUS Market
7D-0.9%-3.5%-6.1%
1Y-40.2%12.7%4.2%

Return vs Industry: AVCO underperformed the US Healthcare industry which returned 12.7% over the past year.

Return vs Market: AVCO underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is AVCO's price volatile compared to industry and market?
AVCO volatility
AVCO Average Weekly Movement9.8%
Healthcare Industry Average Movement8.0%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: AVCO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AVCO's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a7David Jinhttps://www.avalon-globocare.com

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology.

Avalon GloboCare Fundamentals Summary

How do Avalon GloboCare's earnings and revenue compare to its market cap?
AVCO fundamental statistics
Market CapUS$65.59m
Earnings (TTM)-US$9.86m
Revenue (TTM)US$1.45m

45.4x

P/S Ratio

-6.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVCO income statement (TTM)
RevenueUS$1.45m
Cost of RevenueUS$1.06m
Gross ProfitUS$382.32k
ExpensesUS$10.24m
Earnings-US$9.86m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin26.42%
Net Profit Margin-681.22%
Debt/Equity Ratio234.8%

How did AVCO perform over the long term?

See historical performance and comparison

Valuation

Is Avalon GloboCare undervalued compared to its fair value and its price relative to the market?

35.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVCO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVCO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AVCO is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: AVCO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVCO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVCO is overvalued based on its PB Ratio (35.4x) compared to the US Healthcare industry average (2.5x).


Future Growth

How is Avalon GloboCare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avalon GloboCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Avalon GloboCare performed over the past 5 years?

-35.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVCO is currently unprofitable.

Growing Profit Margin: AVCO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVCO is unprofitable, and losses have increased over the past 5 years at a rate of 35.3% per year.

Accelerating Growth: Unable to compare AVCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVCO is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).


Return on Equity

High ROE: AVCO has a negative Return on Equity (-531.74%), as it is currently unprofitable.


Financial Health

How is Avalon GloboCare's financial position?


Financial Position Analysis

Short Term Liabilities: AVCO's short term assets ($1.3M) do not cover its short term liabilities ($4.5M).

Long Term Liabilities: AVCO's short term assets ($1.3M) do not cover its long term liabilities ($4.0M).


Debt to Equity History and Analysis

Debt Level: AVCO's net debt to equity ratio (206.1%) is considered high.

Reducing Debt: AVCO's debt to equity ratio has increased from 0.8% to 234.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVCO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AVCO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34% each year


Dividend

What is Avalon GloboCare current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVCO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVCO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVCO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

David Jin (53 yo)

no data

Tenure

US$1,002,584

Compensation

Dr. David K. Jin, M.D., Ph D., serves as the Chief Executive Officer and President of Avalon Globocare Corp. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medical Institute and Ansary St...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD1.00M) is above average for companies of similar size in the US market ($USD584.85K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: AVCO's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.


Top Shareholders

Company Information

Avalon GloboCare Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Avalon GloboCare Corp.
  • Ticker: AVCO
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$65.593m
  • Shares outstanding: 88.40m
  • Website: https://www.avalon-globocare.com

Number of Employees


Location

  • Avalon GloboCare Corp.
  • 4400 Route 9 South
  • Suite 3100
  • Freehold
  • New Jersey
  • 7728
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/22 23:04
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.